Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.47 |
| ▸ | PGR | P06401 | 5/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364620 | 1.00 | AR (0.47) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL15713018 | 0.91 | AR (0.42) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL12307978 | 0.86 | AR (0.43) | ARPGRNR3C1NR3C2 | |
| SCHEMBL1363718 | 0.86 | AR (0.43) | ARPGRNR3C1L3MBTL1 | |
| SCHEMBL1363767 | 0.86 | AR (0.43) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL1364665 | 0.86 | AR (0.43) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL1364613 | 0.86 | AR (0.43) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL1363222 | 0.86 | AR (0.43) | ARPGRNR3C1L3MBTL1 | |
| SCHEMBL1365319 | 0.86 | AR (0.43) | ARPGRNR3C1NR3C2CXCR1 | |
| SCHEMBL13747780 | 0.86 | AR (0.48) | ARPGRNR3C1NR3C2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2260028-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009105214-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885NR3C1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.